Filing Details

Accession Number:
0001209191-20-005129
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-01-28 16:02:08
Reporting Period:
2020-01-24
Accepted Time:
2020-01-28 16:02:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1446847 Ironwood Pharmaceuticals Inc IRWD Pharmaceutical Preparations (2834) 043404176
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1478448 A Thomas Mccourt C/O Ironwood Pharmaceuticals, Inc.
100 Summer Street, Suite 2300
Boston MA 02110
President No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2020-01-24 20,000 $10.02 245,239 No 4 M Direct
Class A Common Stock Disposition 2020-01-24 20,000 $12.71 225,239 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class A Common Stock Employee Stock Option (Right to Buy) Disposition 2020-01-24 20,000 $0.00 20,000 $10.02
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2020-02-02 No 4 M Direct
Footnotes
  1. The reporting person acquired 280 shares of Class A common stock under the issuer's employee stock purchase plan on December 31, 2019.
  2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.33 to $12.98, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  4. This option, granted as an annual performance award, is presently exercisable in full.